Responsiveness of Inhaled Epoprostenol in Respiratory Failure due to COVID-19

Inhaled pulmonary vasodilators are used as adjunctive therapies for the treatment of refractory hypoxemia. Available evidence suggest they improve oxygenation in a subset of patients without changing long-term trajectory. Given the differences in respiratory failure due to COVID-19 and "traditional" ARDS, we sought to identify their physiologic impact.

This is a retrospective observational study of patients mechanically ventilated for COVID-19, from the ICUs of 2 tertiary care centers, who received inhaled epoprostenol (iEpo) for the management of hypoxemia. The primary outcome is change in PaO₂/FiO₂. Additionally, we measured several patient level features to predict iEpo responsiveness (or lack thereof).

Eighty patients with laboratory confirmed SARS-CoV2 received iEpo while mechanically ventilated and had PaO₂/FiO₂ measured before and after. The median PaO₂/FiO₂ prior to receiving iEpo was 92 mmHg and interquartile range (74 - 122). The median change in PaO₂/FiO₂ was 9 mmHg (-9 - 37) corresponding to a 10% improvement (-8 - 41). Fifty-percent (40 / 80) met our a priori definition of a clinically significant improvement in PaO₂/FiO₂ (increase in 10% from the baseline value). Prone position and lower PaO₂/FiO₂ when iEpo was started predicted a more robust response, which held after multivariate adjustment. For proned individuals, improvement in PaO₂/FiO₂ was 14 mmHg (-6 to 45) vs. 3 mmHg (-11 - 20), p = 0.04 for supine individuals; for those with severe ARDS (PaO₂/FiO₂ < 100, n = 49) the median improvement was 16 mmHg (-2 - 46).

Fifty percent of patients have a clinically significant improvement in PaO₂/FiO₂ after the initiation of iEpo. This suggests it is worth trying as a rescue therapy; although generally the benefit was modest with a wide variability. Those who were prone and had lower PaO₂/FiO₂ were more likely to respond.